![]() | |
![]() | |
Clinical data | |
---|---|
Pronunciation | /sɛfˈtæzɪdiːm/ sef-TAZ-i-deem |
Trade names | Fortaz, Tazicef, others[1] |
AHFS/Drugs.com | Monograph |
MedlinePlus | a686007 |
License data |
|
Pregnancy category |
|
Routes of administration | Intravenous, intramuscular, inhalation |
Drug class | Third-generation cephalosporin |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 91% (IM) |
Metabolism | negligible |
Elimination half-life | 1.6–2 hours |
Excretion | 90–96% kidney |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.069.720 |
Chemical and physical data | |
Formula | C22H22N6O7S2 |
Molar mass | 546.57 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Ceftazidime, sold under the brand name Fortaz among others, is a third-generation cephalosporin antibiotic useful for the treatment of a number of bacterial infections.[1][5] Specifically it is used for joint infections, meningitis, pneumonia, sepsis, urinary tract infections, malignant otitis externa, Pseudomonas aeruginosa infection, and vibrio infection.[1] It is given by injection into a vein, muscle, or eye.[1][6]
Common side effects include nausea, allergic reactions, and pain at the site of injection.[1] Other side effects may include Clostridium difficile diarrhea.[1] It is not recommended in people who have had previous anaphylaxis to a penicillin.[1] Its use is relatively safe during pregnancy and breastfeeding.[7] It is in the third-generation cephalosporin family of medications and works by interfering with the bacteria's cell wall.[1]
Ceftazidime was patented in 1978 and came into commercial use in 1984.[8] It is on the World Health Organization's List of Essential Medicines.[9] Ceftazidime is available as a generic medication.[1]